Home Oxygen Requalification

To the Editor:
We read with interest the article by Dr. Guyatt and coworkers in a recent issue of CHEST (November 2000) 1 regarding the appropriateness of domiciliary oxygen delivery. Their study found that 32.1% of patients receiving long-term oxygen therapy (LTOT), all of whom would have had to meet the arterial blood gas criteria outlined in the continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease (NOTT) trial 2 to qualify for funding, did not continue to meet the same criteria when evaluated in their study. Based on these findings, they suggested that these patients should be denied further funding for LTOT to achieve economic savings for the health-care system. We have concerns with respect to their conclusions and recommendations.
First, in the NOTT and the long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema trials, 3 hypoxic patients were randomized to their respective study arms, in which they remained for the duration of the trials. Although Pao 2 levels were monitored throughout both trials, they were not used to deny or offer patients oxygen therapy. Since these trials provide the strongest evidence of a mortality benefit for patients with hypoxic lung disease who are receiving LTOT, further studies would be needed to determine whether this benefit is maintained if LTOT is stopped in response to an improved Pao 2 .
Second, Guyatt et al dismissed a physiologic argument that we think may have some validity. They dismissed the possibility that oxygen therapy may result in cardiopulmonary vascular changes that improve ventilation/perfusion matching and result in subsequent improvement in blood gas levels while the patient is at rest. While evidence supporting this specific phenomenon is limited, 4 there is convincing evidence demonstrating that cardiovascular parameters in general are substantially improved with oxygen therapy. 2, 3, 5 This suggests that more study in this area may reveal that LTOT does lead to an improvement of Pao 2 while the patient is breathing room air.
Third, in order to determine whether real economic savings will be achieved by discontinuing funding for patients with advanced lung disease who no longer qualify for LTOT, one needs a proper study to assess the health consequences of this action. For example, such patients who have stopped receiving LTOT may have more exacerbations requiring additional medical assessments, therapeutic interventions, and hospitalizations. In the absence of an overall health economic study, the cost savings suggested are purely related to the cost of the LTOT alone.
Last, Guyatt et al suggested that the discontinuation of LTOT when patients no longer meet qualifying criteria may improve quality of life. We wonder whether patients' sentiments contributed to this hypothesis. Did they ask the subjects who participated in their study whether they would be willing to stop using LTOT if they were found to have an improved Pao 2 level? Did they ask them whether they felt that stopping LTOT would improve their quality of life? Based on our experience with similar patients, we think that the majority would be deeply concerned about discontinuing LTOT. Specifically, we think they would be worried about experiencing a reduction in their exercise tolerance and being unable to maintain an optimal level of activity.
As recommended by all the published guidelines, we agree that patients being evaluated for LTOT should be required to meet qualifying criteria when they are medically stable. However, we feel it would be wrong to use this recent study to justify the disqualification of recipients who have experienced improvements in their Pao 2 levels from receiving LTOT in order to achieve economic savings.
Andrea Drs. Gershon and Chan make a number of thoughtful and interesting points about our article (November 2000). 1 With respect to the Nocturnal Oxygen Therapy Trial design, they are correct that oxygen was not discontinued if patients no longer met the blood gas criteria. The Nocturnal Oxygen Therapy Trial investigators were, however, careful to ensure that patients were stable at baseline. The explanation for the very high incidence of patients not meeting the criteria in our study is likely to be that initial measurements were made while patients were in the process of recovering from an exacerbation.
It is theoretically possible that oxygen could lead to improved ventilation/perfusion relationships. The evidence supporting this phenomenon is very weak. We remain skeptical.
We agree that it is possible that patients who no longer meet the criteria for home oxygen therapy, and in whom oxygen is discontinued, will use other health services more frequently than if their oxygen therapy were continued. As Gershon and Chan imply, the study required to determine whether this occurs would be a randomized trial in which the use of all important health-care resources would be monitored. Indeed, we made this statement in our article: "Definitively resolving this issue would require a randomized trial of alternative organizational systems of oxygen delivery that would include health services utilization among the outcomes." Such a trial would be a very important contribution to the understanding of the optimal use of home oxygen therapy.
Gerson and Chan suggest that many patients would be reluctant to discontinue home oxygen therapy because of fears of reduced exercise tolerance. We agree. However, the evidence that patients who do not meet criteria for life-prolonging oxygen therapy increase exercise tolerance in their daily lives with the use of home oxygen is extremely weak. Indeed, the best study on the subject suggests that they do not. 2 We suspect that oxygen is a very powerful placebo, and patients' reluctance to discontinue home oxygen therapy, despite its burden of inconvenience, is a testimony to this effect. Demonstrating to patients that oxygen does not improve their exercise tolerance may require an N-of-1 randomized trial. 3 Finally, we agree that the mechanism of dealing with the problem that we identified, which we believe is due to patients being tested for home oxygen therapy while unstable, is not to cease funding for oxygen in those who were in stable conditions when initially tested. Rather, we advocate more rigorously ensuring stability before committing a patient to long-term domiciliary oxygen. 
Gordon
Fluoroquinolone Pharmacodynamics and Efficacy
To the Editor:
We were intrigued to see the recent correspondence by Karcic and Khan 1 regarding ciprofloxacin therapy of pneumococcal infections and to the response by Brown and Harwell. 2 One of us (G.S.T.) reviewed this topic in 1994 -1995 and reported clinical and bacteriologic success rates of 94.1% and 90.0%, respectively, from 34 studies of acute exacerbations of chronic bronchitis (AECB) and community-acquired pneumonia of ciprofloxacin and Streptococcus pneumoniae. 3 Analysis of the newer fluoroquinolones reveals slightly higher success rates, but the most important aspect of using these newer class members was alluded to in terms of the application of pharmacodynamics and the selection of resistance. Recent advice from the World Health Organization 4 and the Declaration of Toronto (September 2000) suggest that such parameters be observed and that the most pharmacodynamically potent class member be used. It is evident that use of antimicrobial agents having marginal pharmacodynamic activity will select for first-step mutants and the loss of another weapon in the fight against bacterial resistance. From the fluoroquinolone perspective, it is vital that one does not merely rank these agents based on minimum inhibitory concentration (MIC), but instead use the free, unbound maximum serum concentration (Cmax):MIC ratio or area under the inhibitory curve (AUIC) against the most likely pathogen in a specific condition (Table 1) . 5 For example, in community-acquired pneumonia, S pneumoniae or Haemophilus influenzae in patients with mild-to-moderate AECB should be the desired microbial targets. Ideally, the chosen agent should be equally potent against both of these pathogens as well as the atypical pathogens. For fluoroquinolone monotherapy in community respiratory infections, we would advise prescribers to use the most pharmacodynamically potent agent in this class. To The Editor:
Gary V. Doern, PhD
Doern and Tillotson correctly state in their letter that the clinical success of fluoroquinolones in treating community-acquired pneumococcal pneumonia should be weighed against the fact that their marginal pharmacodynamic activity may allow resistance emergence. Obviously, the most pharmacodynamic agents should be used. We have reviewed 1 eight reports of clinical failures caused by pneumococcus, despite the use of ciprofloxacin.
Davies and colleagues 2 reported clinical failure in 17 of 26 patients with pneumococcal chronic bronchitis exacerbations treated with ciprofloxacin. It is possible that this study was flawed, since two lots of medications were used in four different therapeutic regimens. Lee et al 3 reported three failures of pneumococcal upper respiratory tract infection therapy with ciprofloxacin. One patient with otitis media died. Colville et al 4 reported two patients with pneumococcal pneumonia unsuccessfully treated with ciprofloxacin but responding to amoxicillin.
During our early clinical trials, 1 we were often surprised with the clinical success rate of ciprofloxacin in pneumococcal respiratory tract infections, even in the presence of high minimum inhibitory concentrations (MICs). While the reasons for this may be speculative, it is our belief that the excellent penetration of ciprofloxacin into lung tissue 5 
Incidence of Pleuropulmonary Symptoms in Ankylosing Spondylitis
I read with interest the Roentgenogram of the Month by Thai et al . 1 This is an excellent example of a patient with ankylosing spondylitis and apical fibrobullous disease. In the discussion, the author states that ". . .the true incidence of fibrobullous lung disease. . . is not known, but reports range from 1 to 30%." This statement is incorrect. Our previous comprehensive and thorough review of 2,080 patients clarified the incidence of apical fibrobullous disease. 2 A total of 28 patients (an incidence of 1.3%) had pleuropulmonary manifestations of ankylosing spondylitis. This is the definitive report in the English-language literature. We clearly established an incidence figure between 1% and 2%. Hopefully, this figure has now been corrected and future reports will reflect the true incidence of this uncommon disorder. To the Editor:
C. Vaughn
We welcome the comments of Dr. Strimlan in response to our Roentgenogram of the Month article (December 2000) regarding apical fibrocavitary disease in a patient with ankylosing spondylitis. 1 In their article 2 as well as in other review articles, 3,4 a range of reported incidence of pleuropulmonary manifestations in ankylosing spondylitis quoted is 0 to 30%. However, in several original articles, the pathology was nonspecific fibrosis rather than apical fibrocavitary disease related to ankylosing spondylitis. In a review of 42 patients with ankylosing spondylitis, Chakera et al 5 found upper-lobe fibrosis in 6 patients (14.3%) in addition to focal pulmonary changes in 13 patients (30.9%). Interestingly, none of their patients developed cavities. Wolson and Rohwedder 6 found unexplained upper-zone fibrosis in 2 of the 52 patients with typical skeletal radiologic features of ankylosing spondylitis. In their follow-up, one patient developed a mycetoma in the area of fibrosis and the other patient showed no progression of fibrosis. Crompton et al 7 found unexplained pleuropulmonary abnormalities in 14 of 225 patients (12%). Upper-lobe fibrosis was found in 12 of these 14 patients. In only one patient was there evidence of cavitation. We concur with Dr. Strimlan that apical fibrobullous disease is indeed an uncommon entity in patients with ankylosing spondylitis, as has been established in their large series. 2 
Rita S. Ratani, MD
Divya Thai, MD 
Pharmacoeconomics of COPD and Smoking Cessation
In the November issue of CHEST, Hilleman et al 1 published valuable information on the direct financial costs of providing care for patients with COPD. Although the authors provide the valuable information that the annual health-care cost of stage III COPD is much higher ($10,812) than stage I COPD ($1,681), and itemize direct costs, there is important information in their article that goes without comment.
For example, although 26% of patients with stage I COPD are current smokers, there is no mention of costs for nicotine replacement, bupropion, or smoking-cessation counseling. Presumably, the data accurately reflect the fact that COPD patients were not helped with smoking-cessation interventions proven effective in prospective randomized clinical trials. This is not surprising given the current schizophrenic state of the art.
Although the National Institutes of Health, Agency for Healthcare Policy and Research guidelines clearly mandate that all smokers should have nicotine replacement or bupropion prescribed, neither Medicare, nor Medicaid, nor private insurers pay for such treatment. 2 The data of Hilleman et al 1 suggest that this is a costly frugality. Spending $250 to $500 for nicotine replacement and/or bupropion in stage I COPD patients might reasonably be expected to achieve smoking cessation in 30 to 40%. 3 We know from the results of the Lung Health Study that decrements in pulmonary function parallel those in nonsmokers following smoking cessation. 4 It is therefore possible that spending a few dollars on smoking cessation in early stage COPD may prevent or delay progression to advanced COPD, with enormous potential cost savings.
It is time to quit paying "lip service" to preventive medicine, and to provide funding for effective smoking-cessation interventions that will prevent morbidity, mortality, and expense secondary to COPD, cardiovascular disease, neoplasms, and other diseases caused by tobacco products. The money to pay for these treatments is already available in the Ͼ $280 billion Tobacco Master Settlement Agreement, the lion's share of which is now allocated by politicians to such mundane purposes as paving the sidewalks of Los Angeles. More financing can be obtained through a United States Department of Justice lawsuit against the tobacco industry to recover Ͼ $22 billion annual Medicare costs attributable to diseases caused by tobacco products. 5 Frederic W. Grannis 
To the Editor:
We wholeheartedly agree with the recommendations offered by Dr. Grannis. Smoking cessation is clearly a cost-effective approach to reducing the medical consequences and costs of COPD as well as a host of other disease states. Smoking-cessation efforts are underutilized not only in patients with COPD but in other high-risk patient groups, such as those with myocardial infarction. 1 Following Agency for Health Care Policy and Research recommendations to fund smoking-cessation treatment programs and reimbursing providers who offer smoking-cessation treatments should go a long way to stimulate more widespread use of these treatments.
Specific to our study, we clearly were not able to document what percentage of patients had treatment for smoking cessation and, hence, could not identify the costs or cost-effectiveness of such interventions. The most commonly used forms of nicotine replacement therapy (patch and gum) are available over the counter, which limited our ability to capture utilization rates for these products. In addition, bupropion was not generally used for smoking cessation until 1997-1998. Our data collection period extended from 1993-1994 through 1997-1998 . This may be the reason we were unable to document use of this product.
We concur with Dr. Grannis that a significant percentage of the tobacco settlement dollars be used to cover the medical expenses of patients suffering from smoking-related illnesses and for the implementation of both preventative treatment and smoking-cessation interventions.
Daniel E. Hillerman, PharmD The Cardiac Center of Creighton University
Omaha, NE Performing Thoracentesis
To the Editor:
I read with interest the article "Limited Utility of Chest Radiograph After Thoracentesis" by Petersen and Zimmerman in a recent issue of CHEST (April 2000). 1 Although I agree that performing a routine chest radiograph following a thoracentesis is needless in most patients, I was surprised by the number of pneumothoraces that occurred during the performance of thoracentesis, because, in my hands, pneumothorax occurs very rarely (Ͻ 0.025%).
Upon review of the technique described in the article, I advise that during a thoracentesis procedure the tubing attached to the angiocatheter should be utilized in order to ascertain (using the tubing itself as a manometer) what the fluid pressure is in the chest. If the fluid pressure is 0 or even negative, then the removal of fluid will result almost certainly in a pneumothorax, or at worse shock, because one cannot have "a negative space." However, if the fluid pressure is positive, it is very likely that the removal of fluid will not result in a pneumothorax. (In a patient who is borderline, I often recheck the pleural pressure of fluid intermittently during thoracentesis to make sure that I do not remove "too much.") The patient at this point (when the fluid pressure is 0) usually complains of a dull chest pain, which is a reflection of a negative pressure in the chest.
I also was concerned about the authors' disparaging comment about the use of vacuum bottles in performing thoracentesis. I have found that the use of vacuum bottles is an excellent adjunct to the performance of thoracentesis. I have observed that if there is foam at the top of the fluid, then this means that the vacuum is still present; when there is no foam or little foam, there is no vacuum present, which can be indicative of a pneumothorax. Moreover, if a significant pneumothorax is found, I recommend a needle thoracostomy as opposed to chest tube insertion because often the pneumothorax is, at best, transient, when it is caused by such a small needle, as opposed to one induced by trauma.
In closing, I wish to add that the evaluation of fremitus with the stethoscope is a much better test than listening to breath sounds in someone with a pneumothorax. The absence of fremitus is easier to ascertain, whereas the finding of "decreased breath sounds" is sometimes a very difficult physical finding to reproduce. Figures 1 and 2 
Clavicle Tapping and Auscultation as an Alternative to Chest Percussion When Performing Thoracocentesis
Thoracocentesis is a common procedure in medical practice. Chest percussion, however, seems to have become a lost art among medical trainees. Unfortunately, chest percussion remains an important component of assessment when performing thoracocentesis at the bedside, as it allows for the identification of the pleural fluid meniscus, and therefore, the procedure site. The importance of the accurate identification of the superior-most aspect of the pleural effusion when performing thoracocentesis cannot be overstated as inaccurate assessment may needlessly increase the risk of procedural complication, particularly for pneumothorax. The response of many medical centers to the loss of this physical diagnosis skill by clinicians seems to be an increase in the use of ultrasonography and the relegation of thoracocentesis to radiologists. In recent years, we have developed an alternative approach when teaching to our housestaff trainees thoracocentesis that does not rely on chest percussion, namely, clavicle tapping with posterior chest auscultation. Stated simply, this technique takes advantage of the sound transmission characteristics of the inflated lung and the loss of sound transmission caused by the interposition of a layer of fluid between the air-filled lung and the chest wall. A steady tapping of the clavicle anteriorly by the examiner, who is positioned posteriorly reaching over the ipsilateral shoulder, generates a repeating sound that is well-transmitted through the lung to the posterior chest wall and that is readily appreciated via a stethoscope. The stethoscope then is moved slowly inferiorly from the apex to the base with each appreciated tap to the level below which no further conducted sound can be appreciated. This place represents the level of the superior aspect of the pleural effusion.
In our experience, this technique correlates well with chest wall percussion performed by experienced examiners, is readily taught and learned, and has increased the comfort of our housestaff with thoracocentesis. 
Alveolar Hemorrhage Associated With Antiphospholipid Syndrome
Santos-Ocampo et al (October 2000) 1 reviewed seven patients with systemic lupus erythematosus (SLE) admitted to the hospital with episodes of alveolar hemorrhage (AH). Recently, we published a case report of multiple organ dysfunction with acute respiratory failure due to AH associated with antiphospholipid antibodies in a 42-year-old woman with a medical history of antinuclear antibodies-negative SLE and antiphospholipid syndrome (APS). 2 The term antiphospholipid syndrome was introduced to describe patients presenting with combination of recurrent arterial and venous thrombosis, recurrent fetal loss, often accompanied by thrombocytopenia, and elevations of serum antiphospholipid antibodies, eg, lupus anticoagulant (LA) and anticardiolipin antibodies. APS may present as a primary disorder in patients without other autoimmune diseases, or as a secondary disorder in SLE and other autoimmune diseases. 3 An analysis of 29 studies yielded an average frequency of 35% for LA and 44% for anticardiolipin antibodies in SLE patients. The reported frequency of APS in patients with SLE ranges from 20 to 35%. 4 The pulmonary manifestations of APS include multiple pulmonary emboli, major pulmonary arterial thrombosis or microthrombosis with or without capillaritis, pulmonary hypertension, and AH. 5 The presence of antiphospholipid antibodies is not usually associated with hemorrhagic manifestations, and such an event occurring in a patient with the APS is usually due to deficiency of another coagulation factor, severe thrombocytopenia or the presence of severe uremia or hepatic disease. The pulmonary vasculature, however, because of unknown factors, may be susceptible to hemorrhage. 5 In the report of Santos-Ocampo et al, 1 one patient had a medical history of cerebral vascular accident from APS. We are interested to know if all patients were tested for antiphospholipid antibodies, eg, LA and anticardiolipin antibodies or anti-␤ 2 -glycoprotein I antibodies, and AH could also be the result of APS in some of the patients.
Lost in the Labyrinth of End Points
To the Editor:
We feel that the attack on our article in CHEST (October 2000) 1 by Kass and Bartter in their editorial 2 is unjustified on the basis of the data that have been presented. If they had taken care to read the "Materials and Methods" section carefully, they would have clearly seen that the primary outcome variable was the effect on bronchial hyperresponsiveness to adenosine monophosphate challenge, which is a suitable surrogate for mast cell-mediated airway inflammation. On the basis of this end point, there was significant superiority of monotherapy with budesonide over formoterol after 4 weeks, amounting to a 2.5-fold difference. A 1 doubling dilution shift (ie, twofold) in bronchial hyperresponsiveness is usually taken as being a clinically relevant effect. Likewise, there was also a significant difference when comparing these two therapies in the suppression of exhaled nitric oxide, which is another airway inflammatory surrogate. We did not show any difference between combination therapy and budesonide monotherapy for either of these surrogate inflammatory markers, suggesting that any improvements in control with combination therapy are simply due to bronchodilatory activity. For Kass and Bartter to concentrate their editorial on end points of lung function such as FEV 1 and peak expiratory flow, which are insensitive in patients with mild-to-moderate asthma, and which clearly were not chosen as the a priori primary efficacy variable, is to miss the whole rationale of the study, even though we clearly stated the emphasis on the inflammatory markers in the title and in the introduction. Indeed, it has been shown previously that the dose response for inhaled budesonide is much steeper for effects on bronchial hyperresponsiveness than on lung function in patients with mild-to-moderate asthma. 3 To properly evaluate the effects on lung function would require hundreds of patients with more severe asthma, as has already been done in pharmaceutically sponsored multicenter studies.
It was interesting that our patients preferred the treatment regimens that contained formoterol, perhaps suggesting that they had acquired a taste for its rapid effect on airway caliber. We believe that this response may lull patients into a false sense of security, especially if they receive a suboptimal dose of an inhaled steroid before considering adding in the long-acting ␤ 2 -agonist. It was evident from a multicenter study that optimizing the dose of budesonide alone to 800 g/d had a significantly greater impact on severe exacerbations than did the addition of formoterol to budesonide, 200 g/d (ie, a 49% vs 26% reduction). 4 This is especially pertinent as two different fixed-dose combination therapy inhalers (fluticasone-salmeterol and budesonide-formoterol) will soon be available in the United States. These are being aggressively marketed for use in patients with all grades of asthma when there is ample evidence to show that a low-to-medium dose of an inhaled steroid will suffice in most cases of mild-to-moderate asthma. While there is convincing independent evidence to support the use of long-acting ␤-agonists as steroid-sparing agents in cases of more severe persistent asthma, these studies had a duration of only 6 to 12 months and have not evaluated bronchial biopsy, especially over a longer period of several years to see whether using a lower dose of inhaled steroid is associated with irreversible airway damage due to putative airway remodeling. Until such long-term data are available, it makes more sense to use long-acting ␤ 2 -agonists on a as-required basis rather than on a regular basis, once the dose of inhaled steroid has been optimized, perhaps using bronchial hyperresponsiveness in addition to other control markers to titrate the dose, as suggested by the study of Sont et al. 5 We never intended to make sweeping implications on the basis of our small study, but we hope it will make prescribers appraise their choices for each individual patient more carefully.
Erratum
In the December 2000 issue, the article "Surgery for Second Lung Cancers" (CHEST 2000; 118:1621-1625), by Asaph et al, contained an error. On page 1623, the second sentence should read "Twenty-eight patients underwent a preoperative bronchoscopy, in which the second neoplasm was confirmed in 13 patients (46% of those receiving bronchoscopy; Table 1 )."
